{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_941ef0447ae036d561852aa0d5312fbdc2c7da3868008e11627714d75235449d","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_941ef0447ae036d561852aa0d5312fbdc2c7da3868008e11627714d75235449d","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"4b7212ecfd87cc8cb24a8ee2fdc38a1cac971e1c1caaad2b22d17e3c29815c4f","published":"Fri, 12 Jun 2026 00:00:00 -0400","receipt_hash":"4b7212ecfd87cc8cb24a8ee2fdc38a1cac971e1c1caaad2b22d17e3c29815c4f","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"4b7212ecfd87cc8cb24a8ee2fdc38a1cac971e1c1caaad2b22d17e3c29815c4f","observed_at":"2026-06-12T04:43:44.933383Z","parent_run_hash":"a8b304a31db3809a528f5a45e58597f7bb9f23028e53b4f9ed2f5599dd731b5e","published":"Fri, 12 Jun 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2606.12991v1 Announce Type: new \nAbstract: Cyclic peptides represent a promising class of therapeutic compounds in modern drug discovery, often offering improved stability and binding affinity. However, the de novo design of cyclic peptides remains challenging because methods must identify pocket-adaptive cyclization patterns and linkage sites while simultaneously controlling drug-relevant properties. This challenge is particularly pronounced for recent generative models trained predominantly on linear peptide data, which may fail to capture cyclization-specific constraints. To address the limitation, we introduce APCyc, a target-aware de novo cyclic peptide generation framework that explicitly models cyclization and jointly optimizes multiple essential physicochemical properties. By using an expanded residue vocabulary and explicitly encoding cyclization-site and linkage-type information, APCyc learns cyclization-aware representations and leverages Bayesian posterior guidance to","title":"APCyc: Property-Informed Design of Cyclic Peptides via Automated Cyclization","url":"https://arxiv.org/abs/2606.12991","vendor":"arxiv_cs_ai"},"summary":"arXiv:2606.12991v1 Announce Type: new \nAbstract: Cyclic peptides represent a promising class of therapeutic compounds in modern drug discovery, often offering improved stability and binding affinity. However, the de novo design of cyclic peptides remains challenging because methods must identify pocket-adaptive cyclization patterns and linkage sites while simultaneously controlling drug-relevant properties. This challenge is particularly pronounced for recent generative models trained predominantly on linear peptide data, which may fail to capture cyclization-specific constraints. To address the limitation, we introduce APCyc, a target-aware de novo cyclic peptide generation framework that explicitly models cyclization and jointly optimizes multiple essential physicochemical properties. By using an expanded residue vocabulary and explicitly encoding cyclization-site and linkage-type information, APCyc learns cyclization-aware representations and leverages Bayesian posterior guidance to","title":"APCyc: Property-Informed Design of Cyclic Peptides via Automated Cyclization","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-06-12T04:43:44Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2606.12991"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:09357ee67a88d65e3b5e8471db389b634b1bc8dcbee15138756482ace5a08c41b1b861f49585667c647185018cb0d3d0f8d70c3cabe2642daa758d490b777e0b","signer":"crovia.substrate","subject":{"observed_at":"2026-06-12T04:43:44Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2606.12991"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"c06f03fab1de40468c0873f3ef1f41052cdb4c990e559400f189867778082f35","leaf_index":229624,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"289a5374a71837b5990d2d518a66f1508c091196a5e68eac9f4f03fcceb27ec9","side":"right"},{"sibling":"485739045279d17fb688a8a398a276a8778557d3ed58a1d7633b0287de5baf08","side":"right"},{"sibling":"b49e7f7d88876e303687b8a01026c7c17291037d81ac793b07604166a977ba61","side":"right"},{"sibling":"8722f47125b15319a3629b20cc73ba5dc593cc2a7e63632548657e50dd559a7c","side":"left"},{"sibling":"04e9a585aaf8e3d1a84a17f77c5df2b888cc334c085a748f4f3679984597f4d5","side":"left"},{"sibling":"130ba5a74164633f11f5402c884b61ee34fdc4bc05eb943e584b514e9a216dca","side":"left"},{"sibling":"3ecde8d5b1aef7d87f45b824944efb9ddcb925547ba1b0df184a80b65e3628b2","side":"left"},{"sibling":"036b81c8003605ba78b7f79e8751093f80731187bf2970c7e3a612d0738c622b","side":"left"},{"sibling":"fd035c47cab5aa276f339e8f999b8537ea3a4fa7d9e74ec4c8ff95f5e10a223c","side":"right"},{"sibling":"d385017d38a86f6abc492026a7cd60ceb3b3ff2486142dc49e5acb179f4b7d11","side":"right"},{"sibling":"bde25d7e94e64717e426a97f6fcb4907e92b5c61fc89d92d7e0947a2249c3f6b","side":"right"},{"sibling":"d10d772a4984cae00e65ab24af21d1d260e475bbaae3f17871859eb705bd3999","side":"right"},{"sibling":"e79159853f2f35ddae8e3247d515e433c534277b287d65bbd77ae989aa4992fa","side":"right"},{"sibling":"3054319f1840cce0eaaf0bc4b1ae38e5bf8b6210927d924a750775cc7d77cca6","side":"right"},{"sibling":"0fd8b5059f279c4a4a6688de2472fdbc25543fee183df19b21dacca880354cff","side":"right"},{"sibling":"a04392fb9f2a3a620840e3b3fecd93d12e6d224e481c162389d8ae64e7194599","side":"left"},{"sibling":"c300cf0154c136afc09b1702a0be98f4ba5b6dc5cf57e8cc714ec1eaf4196eff","side":"left"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":232015,"merkle_root":"62bfb7809bb55667ad7eeebdb48267b9b2c1ee89bb808ea1e6d3a814a15aa402","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260617T133701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-06-17T13:39:59Z","sig_algorithm":"ed25519","signature":"930a3563c643cc7518d048b12a1f5392a96a5edce49533ba0a56f11b6cc69319bb1c800aacc46b52a6941c4d05dae255a45cac757d6093c971b96852c24f140e","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_941ef0447ae036d561852aa0d5312fbdc2c7da3868008e11627714d75235449d"}}